Copyright
©The Author(s) 2017.
World J Gastrointest Endosc. Feb 16, 2017; 9(2): 77-84
Published online Feb 16, 2017. doi: 10.4253/wjge.v9.i2.77
Published online Feb 16, 2017. doi: 10.4253/wjge.v9.i2.77
VisiGlide2TM | VisiGlideTM | ||||
Papillary treatment | n | Success rate of procedure | n | Success rate of procedure | P-value |
EST | 67 | 100 (67/67)% | 67 | 100 (67/67)% | NS |
EST + EPLBD | 3 | 100 (3/3)% | 5 | 100 (5/5)% | NS |
EPST | 3 | 100 (3/3)% | 3 | 100 (3/3)% | NS |
EPBD | 1 | 100 (1/1)% | 4 | 100 (4/4)% | NS |
Total | 74 | 100 (74/74)% | 79 | 100 (79/79)% | NS |
- Citation: Sakai Y, Tsuyuguchi T, Hirata N, Nakaji S, Shimura K, Nishikawa T, Fujimoto T, Hamano T, Nishino T, Yokosuka O. Clinical utility of 0.025-inch guidewire VisiGlide2TM in the endoscopic retrograde cholangiopancreatography-related procedures. World J Gastrointest Endosc 2017; 9(2): 77-84
- URL: https://www.wjgnet.com/1948-5190/full/v9/i2/77.htm
- DOI: https://dx.doi.org/10.4253/wjge.v9.i2.77